HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Indaptus Therapeutics (NASDAQ:INDP) and maintained a $12 price target.
April 15, 2024 | 10:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Indaptus Therapeutics with a $12 price target.
The reiteration of a Buy rating and maintenance of a $12 price target by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence among investors and could positively influence Indaptus Therapeutics' stock price in the short term. The specific mention of the company and the reaffirmation of the price target suggest a strong belief in the company's potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100